RT Journal
A1 Steinbrook R
T1 PReexposure prophylaxis for hiv infection
JF JAMA
JO JAMA
YR 2012
FD September 5
VO 308
IS 9
SP 865
OP 866
DO 10.1001/jama.2012.9885
UL http://dx.doi.org/10.1001/jama.2012.9885
AB 
On July 16, 2012, the US Food and Drug Administration (FDA) approved a daily oral antiretroviral drug to reduce the risk of sexual acquisition of human immunodeficiency virus (HIV) infection by uninfected adults.1- 2 Emtricitabine/tenofovir disoproxil fumarate (marketed by Gilead as Truvada) contains 2 nucleoside analogue HIV-1 reverse transcriptase inhibitors. Initially approved in 2004 to treat HIV infection in combination with other antiretroviral medications in people 12 years of age and older, emtricitabine/tenofovir costs about $13 900 a year in the United States for a year of treatment.